Abbott to acquire Sanofi Carpuject injectable system, multi-source line for about $200 mil.
Executive Summary
ABBOTT TO ACQUIRE SANOFI CARPUJECT INJECTABLE LINE FOR APPROXIMATELY $200 MIL. in a deal expected to close this summer, Abbott said April 29. The acquisition will give Abbott worldwide rights to Sanofi's Carpuject line of pre-filled, single-dose syringes. In addition to Carpuject, Abbott will obtain Sanofi's line of multi-source injectable drugs, including anesthetics such as Marcaine (bupivacaine), analgesics, central nervous system drugs and cardiovascular drugs. Sanofi's Primacor (milrinone lactate) and Inocor (amrinone lactate) injections are not included in the deal.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth